Categories | Peptide Database

YK-11's dual mechanism of AR agonism and myostatin inhibition theoretically positions it as a potent anabolic compound for increasing lean muscle mass. Cell culture data supports increased anabolic signaling and follistatin expression. However, there is no in vivo or clinical evidence confirming these effects in animals or humans. All efficacy reports are anecdotal. Users anecdotally report significant strength gains during YK-11 cycles, consistent with the compound's theoretical mechanism of action. The combination of AR-mediated protein synthesis and myostatin inhibition could theoretically support enhanced force production. No controlled studies exist to verify these claims. The most distinctive proposed benefit of YK-11 is its ability to upregulate follistatin and thereby inhibit myostatin-mediated limitations on muscle growth. In cell culture, YK-11 induced greater follistatin expression than DHT. If this translates to in vivo activity, it could allow muscle growth beyond normal physiological limits. This remains entirely unproven outside of cell-based assays. Follistatin has been shown in other research contexts to positively influence bone mineral density and bone formation. If YK-11's follistatin-inducing effects translate in vivo, there could be secondary benefits for bone density. This is entirely speculative and unsupported by any direct YK-11 bone data.

Join others researching Proviron — share findings, ask questions, and learn from real experiences Proviron (mesterolone) is an orally active dihydrotestosterone (DHT) derivative that has been used in clinical medicine since the 1960s, primarily in Europe and other international markets. Unlike most oral anabolic steroids, Proviron is not 17-alpha alkylated, which gives it a remarkably low hepatotoxicity profile. It was originally developed for the treatment of androgen deficiency, male infertility (at low doses it can improve sperm quality without fully suppressing the HPT axis), and mood disturbances related to low androgen status. Proviron is approved in numerous countries outside the United States including Germany, the UK, and several countries across Asia, South America, and the Middle East. Its most distinctive pharmacological property is its exceptionally strong binding affinity for sex hormone-binding globulin (SHBG), which effectively displaces testosterone from SHBG and increases the proportion of circulating free testosterone. This mechanism makes Proviron a popular adjunct to testosterone replacement therapy and performance enhancement protocols, where it amplifies the biological activity of co-administered testosterone without meaningfully increasing total androgen load. Proviron is also valued for its anti-estrogenic properties — as a DHT derivative, it cannot aromatize to estrogen, and it competes with testosterone for the aromatase enzyme, reducing overall estrogen conversion. Users consistently report improvements in mood, libido, confidence, and a general sense of well-being, along with a harder, drier, and more defined physical appearance. Proviron exerts its effects primarily through direct binding to the androgen receptor (AR) as a potent DHT analogue. However, its most therapeutically relevant mechanism is its exceptionally high binding affinity for sex hormone-binding globulin (SHBG). By occupying SHBG binding sites, Proviron displaces testosterone that would otherwise be bound and biologically inactive, effectively increasing free testosterone levels without requiring additional exogenous testosterone. This SHBG-displacement mechanism is the primary reason Proviron is considered synergistic with testosterone — it amplifies the effective androgenic signal from a given dose of testosterone. Proviron also acts as a mild aromatase inhibitor. Because it is a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, and it competes with aromatizable androgens (like testosterone) for access to aromatase, reducing the overall rate of estrogen conversion. This dual mechanism — increasing free testosterone while reducing estrogen — produces the characteristic effects of improved mood, enhanced libido, and the harder, drier physique that Proviron is known for. In muscle tissue, Proviron's anabolic effects are limited because it is rapidly inactivated by 3-alpha hydroxysteroid dehydrogenase, similar to DHT itself. This enzyme is highly expressed in skeletal muscle, which is why Proviron is not considered a significant muscle-building agent on its own but rather an enhancer of other androgens.